Skip to main content
main-content

Latest news

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Breaking headlines, in-depth features, hot topic review articles, and 

the latest from major international conferences brought to you by


DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

New Content Item

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

Type 2 diabetes, polyvascular disease combine to increase cardiovascular risk

Heartbeat

Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.

Latest headlines

12-11-2018 | SGLT2 inhibitors | News

Meta-analysis supports cardioprotective benefits of SGLT2 inhibitors

Sodium-glucose cotransporter 2 inhibitors reduce the risk for heart failure hospitalization and renal disease progression in patients with type 2 diabetes regardless of existing cardiovascular disease, meta-analysis data show.

09-11-2018 | Adolescents | News

Elevated multiple complication risk in youth with type 1 diabetes

Patients with type 1 diabetes may develop multiple complications even before they reach adulthood, shows an analysis of the SEARCH for Diabetes in Youth Study.

08-11-2018 | Nephropathy | News

Novel VAP-1 inhibitor shows promise for diabetic kidney disease

The novel, orally active vascular adhesion protein-1 inhibitor ASP8232 effectively reduces albuminuria, with few side effects, in patients with type 2 diabetes and chronic kidney disease, phase II study data show.

Features and expert interviews

30-09-2018 | UKPDS | Feature | Article

The UKPDS: A lasting legacy

Twenty years after the publication of the primary findings, medwireNews talks to longtime UKPDS investigator Professor David Matthews (University of Oxford, UK) about the struggles of the team to bring the trial to completion and the impact of the findings on diabetes care.

27-03-2018 | Inpatient diabetes | Feature | Article

The inpatient diabetes audit: A tool for change

With the 2017 NaDIA results showing some positive trends in inpatient diabetes care, medwireNews talks to national clinical lead Gerry Rayman about the tools and tactics to deliver the best patient outcomes.

Metabolically healthy obesity: Laying a controversial concept to rest

The concept of metabolically healthy obesity has produced huge numbers of seemingly contradictory studies, and polarized opinion among researchers. medwireNews looks back at the big data, the high-impact publications, and the underlying hypotheses that helped the concept to persist for so long, and asks if the field has finally reached consensus.

image credits